Switch to:
Also traded in: Germany, South Africa

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.21
APNHF's Cash-to-Debt is ranked lower than
86% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. APNHF: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
APNHF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.34 Max: 128.44
Current: 0.21
0.21
128.44
Equity-to-Asset 0.37
APNHF's Equity-to-Asset is ranked lower than
83% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. APNHF: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
APNHF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.45 Max: 0.55
Current: 0.37
0.31
0.55
Debt-to-Equity 1.14
APNHF's Debt-to-Equity is ranked lower than
86% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. APNHF: 1.14 )
Ranked among companies with meaningful Debt-to-Equity only.
APNHF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.7 Max: 1.55
Current: 1.14
0.01
1.55
Debt-to-EBITDA 6.44
APNHF's Debt-to-EBITDA is ranked lower than
85% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. APNHF: 6.44 )
Ranked among companies with meaningful Debt-to-EBITDA only.
APNHF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02  Med: 2.56 Max: 6.44
Current: 6.44
0.02
6.44
Interest Coverage 3.75
APNHF's Interest Coverage is ranked lower than
84% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. APNHF: 3.75 )
Ranked among companies with meaningful Interest Coverage only.
APNHF' s Interest Coverage Range Over the Past 10 Years
Min: 3.11  Med: 4.82 Max: 5.91
Current: 3.75
3.11
5.91
Piotroski F-Score: 5
Altman Z-Score: 2.59
Beneish M-Score: -2.45
WACC vs ROIC
10.13%
7.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 19.79
APNHF's Operating Margin % is ranked higher than
81% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. APNHF: 19.79 )
Ranked among companies with meaningful Operating Margin % only.
APNHF' s Operating Margin % Range Over the Past 10 Years
Min: 19.79  Med: 25.66 Max: 26.74
Current: 19.79
19.79
26.74
Net Margin % 9.76
APNHF's Net Margin % is ranked higher than
62% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. APNHF: 9.76 )
Ranked among companies with meaningful Net Margin % only.
APNHF' s Net Margin % Range Over the Past 10 Years
Min: 9.76  Med: 18.03 Max: 20.82
Current: 9.76
9.76
20.82
ROE % 8.86
APNHF's ROE % is ranked higher than
57% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. APNHF: 8.86 )
Ranked among companies with meaningful ROE % only.
APNHF' s ROE % Range Over the Past 10 Years
Min: 8.86  Med: 20.48 Max: 38.57
Current: 8.86
8.86
38.57
ROA % 3.49
APNHF's ROA % is ranked lower than
51% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. APNHF: 3.49 )
Ranked among companies with meaningful ROA % only.
APNHF' s ROA % Range Over the Past 10 Years
Min: 3.49  Med: 9.51 Max: 12.24
Current: 3.49
3.49
12.24
ROC (Joel Greenblatt) % 29.17
APNHF's ROC (Joel Greenblatt) % is ranked higher than
72% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. APNHF: 29.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
APNHF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 29.17  Med: 63.55 Max: 146.66
Current: 29.17
29.17
146.66
3-Year Revenue Growth Rate 22.60
APNHF's 3-Year Revenue Growth Rate is ranked higher than
87% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. APNHF: 22.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
APNHF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 15  Med: 23.3 Max: 33.4
Current: 22.6
15
33.4
3-Year EBITDA Growth Rate 22.60
APNHF's 3-Year EBITDA Growth Rate is ranked higher than
72% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. APNHF: 22.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
APNHF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 24.1 Max: 46.5
Current: 22.6
0
46.5
3-Year EPS without NRI Growth Rate 7.00
APNHF's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. APNHF: 7.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
APNHF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 7  Med: 26.6 Max: 365.5
Current: 7
7
365.5
GuruFocus has detected 6 Warning Signs with Aspen Pharmacare Holdings Ltd APNHF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» APNHF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with APNHF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:XPAR:IPN, OCSE:LUN, SHSE:600196, NYSE:PRGO, TSE:4508, BOM:532321, HKSE:03320, XSWX:VIFN, SZSE:000538, SZSE:000963, SHSE:603858, BOM:500257, SHSE:600085, BSP:HYPE3, OHEL:ORNBV, SZSE:300122, SZSE:000423, NSE:AUROPHARMA, SHSE:600332, TSE:4581 » details
Traded in other countries:LDZA.Germany, APN.South Africa,
Headquarter Location:South africa
Aspen Pharmacare Holdings Ltd through its subsidiaries, is engaged in manufacturing, marketing and distribution of branded and generic pharmaceutical, as well as nutritional products.

Aspen Pharmacare Holdings is a specialty and generic drug manufacturing company. The company maintains a focus on four therapeutic categories: thrombosis, anaesthetics, high potency and cytotoxics, and infant nutritionals. Aspen generates the vast majority of its revenue through its commercial-pharma segment, followed by manufacturing and commercial-nutritionals segments. The company considers potential merger and acquisition investment a component of its operational growth strategy to expand its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Aspen Pharmacare Holdings Ltd

Vanguard Health Care Fund Gains 5 New Stocks 2 of the fund’s new holdings recently went public
The Vanguard Health Care Fund (Trades, Portfolio) established five new holdings in the final quarter of 2016. The holdings are ConvaTec Group PLC (LSE:CTEC), Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Samsung BioLogics Co. Ltd. (XKRX:207940), Shanghai Fosun Pharmaceutical Group Co. Ltd. (SHSE:600196) and Aspen Pharmacare Holdings Ltd. (JSE:APN). Read more...

Ratios

vs
industry
vs
history
PE Ratio 38.72
APNHF's PE Ratio is ranked lower than
68% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. APNHF: 38.72 )
Ranked among companies with meaningful PE Ratio only.
APNHF' s PE Ratio Range Over the Past 10 Years
Min: 12.7  Med: 22.48 Max: 40.2
Current: 38.72
12.7
40.2
PE Ratio without NRI 38.72
APNHF's PE Ratio without NRI is ranked lower than
67% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. APNHF: 38.72 )
Ranked among companies with meaningful PE Ratio without NRI only.
APNHF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.99  Med: 24.21 Max: 40.2
Current: 38.72
12.99
40.2
PB Ratio 3.73
APNHF's PB Ratio is ranked lower than
60% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. APNHF: 3.73 )
Ranked among companies with meaningful PB Ratio only.
APNHF' s PB Ratio Range Over the Past 10 Years
Min: 2.66  Med: 4.11 Max: 7.5
Current: 3.73
2.66
7.5
PS Ratio 4.15
APNHF's PS Ratio is ranked lower than
59% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. APNHF: 4.15 )
Ranked among companies with meaningful PS Ratio only.
APNHF' s PS Ratio Range Over the Past 10 Years
Min: 2.27  Med: 3.79 Max: 6.78
Current: 4.15
2.27
6.78
Price-to-Free-Cash-Flow 369.95
APNHF's Price-to-Free-Cash-Flow is ranked lower than
98% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. APNHF: 369.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
APNHF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 22.73  Med: 76.59 Max: 433.79
Current: 369.95
22.73
433.79
Price-to-Operating-Cash-Flow 46.23
APNHF's Price-to-Operating-Cash-Flow is ranked lower than
85% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. APNHF: 46.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
APNHF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.81  Med: 24.53 Max: 54.21
Current: 46.23
14.81
54.21
EV-to-EBIT 26.19
APNHF's EV-to-EBIT is ranked lower than
64% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. APNHF: 26.19 )
Ranked among companies with meaningful EV-to-EBIT only.
APNHF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 17.95 Max: 29.6
Current: 26.19
6.8
29.6
EV-to-EBITDA 26.19
APNHF's EV-to-EBITDA is ranked lower than
71% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. APNHF: 26.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
APNHF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 16.8 Max: 28.1
Current: 26.19
6.8
28.1
EV-to-Revenue 4.84
APNHF's EV-to-Revenue is ranked lower than
62% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. APNHF: 4.84 )
Ranked among companies with meaningful EV-to-Revenue only.
APNHF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 4.5 Max: 7.8
Current: 4.84
1.8
7.8
PEG Ratio 1.23
APNHF's PEG Ratio is ranked higher than
69% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. APNHF: 1.23 )
Ranked among companies with meaningful PEG Ratio only.
APNHF' s PEG Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1 Max: 2.28
Current: 1.23
0.37
2.28
Shiller PE Ratio 48.42
APNHF's Shiller PE Ratio is ranked lower than
59% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. APNHF: 48.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
APNHF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 39.36  Med: 56.69 Max: 90.84
Current: 48.42
39.36
90.84
Current Ratio 1.48
APNHF's Current Ratio is ranked lower than
73% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. APNHF: 1.48 )
Ranked among companies with meaningful Current Ratio only.
APNHF' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.4 Max: 1.95
Current: 1.48
0.7
1.95
Quick Ratio 0.94
APNHF's Quick Ratio is ranked lower than
78% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. APNHF: 0.94 )
Ranked among companies with meaningful Quick Ratio only.
APNHF' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.97 Max: 1.31
Current: 0.94
0.49
1.31
Days Inventory 257.63
APNHF's Days Inventory is ranked lower than
91% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. APNHF: 257.63 )
Ranked among companies with meaningful Days Inventory only.
APNHF' s Days Inventory Range Over the Past 10 Years
Min: 115.22  Med: 143.67 Max: 259.83
Current: 257.63
115.22
259.83

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate 11.20
APNHF's 3-Year Dividend Growth Rate is ranked higher than
60% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. APNHF: 11.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
APNHF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.2 Max: 63.4
Current: 11.2
0
63.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.00
APNHF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. APNHF: 3.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
APNHF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 3.82 Max: 5.84
Current: 3
0
5.84
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.36
APNHF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
58% of the 85 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. APNHF: 1.36 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
APNHF' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.96  Med: 1.11 Max: 1.35
Current: 1.36
0.96
1.35
Price-to-Median-PS-Value 1.10
APNHF's Price-to-Median-PS-Value is ranked lower than
99.99% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. APNHF: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
APNHF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.9 Max: 1.42
Current: 1.1
0
1.42
Price-to-Peter-Lynch-Fair-Value 1.37
APNHF's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. APNHF: 1.37 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
APNHF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.99 Max: 1.81
Current: 1.37
0
1.81
Earnings Yield (Greenblatt) % 3.82
APNHF's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. APNHF: 3.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
APNHF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 5.6 Max: 14.8
Current: 3.82
3.4
14.8
Forward Rate of Return (Yacktman) % 28.39
APNHF's Forward Rate of Return (Yacktman) % is ranked higher than
85% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. APNHF: 28.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
APNHF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.6  Med: 28.3 Max: 38.7
Current: 28.39
1.6
38.7

More Statistics

Revenue (TTM) (Mil) $2,633.53
EPS (TTM) $ 0.59
Beta1.52
Short Percentage of Float0.00%
52-Week Range $18.76 - 23.92
Shares Outstanding (Mil)456.00

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

» More Articles for APNHF

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Gains 5 New Stocks Feb 01 2017 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}